Skip to main content
. Author manuscript; available in PMC: 2015 May 19.
Published in final edited form as: Prostate. 2013 Oct 16;74(2):201–209. doi: 10.1002/pros.22741

Figure 1. Overexpression of IL-6 increases LNCaP cell resistance to enzalutamide.

Figure 1

A: LNCaP cells stably expressing IL6 (LNCaP-s17) and control LNCaP cells (LNCaP-neo) were treated with different doses of enzalutamide in media containing complete FBS. Total cell numbers were counted after 48 h and cell survival rates were calculated as described in the methods. Results are presented as means ± SD of 3 experiments performed in duplicate. B: LNCaP-neo and LNCaP-s17 cells were treated with 0 or 20 µM enzalutamide and clonogenic assays were performed. C: Colonies were counted and results are presented as means ± SD of 2 experiments performed in duplicate. LNCaP-s17 cells formed higher numbers of colonies compared to LNCaP-neo cells when treated with enzalutamide. D: LNCaP-IL6+ cells (continuous culture in medium containing 10% FBS and 5 ng/mL IL-6) and control LNCaP cells were treated with 0, 10 or 20 µM enzalutamide in media containing complete FBS and cell numbers were counted after 48 h. Results are presented as means ± SD of 3 experiments performed in duplicate. * P <0.05.